



H Rosing

Contact

H Rosing

Publications (6)

Jörger M, Beijnen J, Cerny T, Meulendijks D, Zueger M, Meijerman I, Rosing H, Vainchtein L, Smits P, Doodeman V, Cats A, Boot H, Huitema A, Schellens J. Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy. *Cancer Chemother Pharmacol* 2015; 75:763-72.

Jörger M, Huitema A, Koeberle D, Rosing H, Beijnen J, Hitz F, Cerny T, Schellens J, Gillessen Sommer S. Safety and pharmacology of gemcitabine and capecitabine in patients with advanced pancreatico-biliary cancer and hepatic dysfunction. *Cancer Chemother Pharmacol* 2013; 73:113-24.

Jörger M, Beijnen J, Huitema A, Rosing H, Vainchtein L, Jansen R, Smits P, Doodeman V, Baas P, Burgers J, Schellens J. Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine. *Cancer Chemother Pharmacol* 2011; 69:25-33.

Jörger M, Huitema A, Huizing M, Willemsse P, de Graeff A, Rosing H, Schellens J, Beijnen J, Vermorken J. Safety and pharmacology of paclitaxel in patients with impaired liver function: a population pharmacokinetic-pharmacodynamic study. *British journal of clinical pharmacology* 2007; 64:622-33.

Brouwers E, Tibben M, Rosing H, Hillebrand M, Jörger M, Schellens J, Beijnen J. Sensitive inductively coupled plasma mass spectrometry assay for the determination of platinum originating from cisplatin, carboplatin, and oxaliplatin in human plasma ultrafiltrate. *Journal of mass spectrometry : JMS* 2006; 41:1186-94.

Brouwers E, Tibben M, Jörger M, van Tellingen O, Rosing H, Schellens J, Beijnen J. Determination of oxaliplatin in human plasma and plasma ultrafiltrate by graphite-furnace atomic-absorption spectrometry. *Analytical and bioanalytical chemistry* 2005; 382:1484-90.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch